RATIONALE: Bronchiolitis obliterans (BO) is a major problem in lung transplantation and is also part of the spectrum of late-onset pulmonary complications that can occur after hematopoietic stem cell transplant. Better mouse models are needed to study the onset of this disease so that therapeutic interventions can be developed. OBJECTIVES: Our goal was to develop a BO mouse model. METHODS: Recipients were lethally conditioned and given a rescue dose of T-cell-depleted, allogeneic bone marrow (BM) supplemented with a sublethal dose of allogeneic T cells. MEASUREMENTS AND MAIN RESULTS: At 2 months post-BM transplant, the lungs had extensive perivascular and peribronchiolar inflammation consisting of CD4(+) T cells, CD8(+) T cells, B cells, macrophages, neutrophils, and fibroblasts. In contrast to the acute model, histology showed airway obstruction consistent with BO. Epithelial cells of airways in the early stages of occlusion exhibited changes in expression of cytokeratins. Although the lung had severe allogeneic BM transplant-mediated disease, there was only mild to moderate graft-versus-host disease in liver, colon, skin, and spleen. High wet/dry weight ratios and elevated hydroxyproline were seen, consistent with pulmonary edema and fibrosis. Mice with BO exhibited high airway resistance and low compliance. Increases in many inflammatory mediators in the lungs of mice that develop BO were seen early post-transplant and not later at the time of BO. CONCLUSIONS: This new mouse model will be useful for the study of BO associated with late post-hematopoietic stem cell transplant onset and chronic graft-versus-host disease, which also leads to poor outcome in the lung transplant setting.
RATIONALE: Bronchiolitis obliterans (BO) is a major problem in lung transplantation and is also part of the spectrum of late-onset pulmonary complications that can occur after hematopoietic stem cell transplant. Better mouse models are needed to study the onset of this disease so that therapeutic interventions can be developed. OBJECTIVES: Our goal was to develop a BO mouse model. METHODS: Recipients were lethally conditioned and given a rescue dose of T-cell-depleted, allogeneic bone marrow (BM) supplemented with a sublethal dose of allogeneic T cells. MEASUREMENTS AND MAIN RESULTS: At 2 months post-BM transplant, the lungs had extensive perivascular and peribronchiolar inflammation consisting of CD4(+) T cells, CD8(+) T cells, B cells, macrophages, neutrophils, and fibroblasts. In contrast to the acute model, histology showed airway obstruction consistent with BO. Epithelial cells of airways in the early stages of occlusion exhibited changes in expression of cytokeratins. Although the lung had severe allogeneic BM transplant-mediated disease, there was only mild to moderate graft-versus-host disease in liver, colon, skin, and spleen. High wet/dry weight ratios and elevated hydroxyproline were seen, consistent with pulmonary edema and fibrosis. Mice with BO exhibited high airway resistance and low compliance. Increases in many inflammatory mediators in the lungs of mice that develop BO were seen early post-transplant and not later at the time of BO. CONCLUSIONS: This new mouse model will be useful for the study of BO associated with late post-hematopoietic stem cell transplant onset and chronic graft-versus-host disease, which also leads to poor outcome in the lung transplant setting.
Authors: Marc Estenne; Janet R Maurer; Annette Boehler; James J Egan; Adaani Frost; Marshall Hertz; George B Mallory; Gregory I Snell; Samuel Yousem Journal: J Heart Lung Transplant Date: 2002-03 Impact factor: 10.247
Authors: Bekele Afessa; Ayalew Tefferi; Mark R Litzow; Michael J Krowka; Mark E Wylam; Steve G Peters Journal: Am J Respir Crit Care Med Date: 2002-09-01 Impact factor: 21.405
Authors: Isabel P Neuringer; Robert M Aris; Kim A Burns; Tracy L Bartolotta; Worakij Chalermskulrat; Scott H Randell Journal: Am J Transplant Date: 2002-05 Impact factor: 8.086
Authors: K D Markopoulo; C D Cool; T L Elliot; D A Lync; J D Newell; V A Hale; K K Brown; M I Schwarz; R M Tuder Journal: Eur Respir J Date: 2002-01 Impact factor: 16.671
Authors: John A Belperio; Bruno DiGiovine; Michael P Keane; Marie D Burdick; Ying Ying Xue; David J Ross; Joseph P Lynch; Steven L Kunkel; Robert M Strieter Journal: Transplantation Date: 2002-02-27 Impact factor: 4.939
Authors: T R Ziegler; A Panoskaltsus-Mortari; L H Gu; C R Jonas; C L Farrell; D L Lacey; D P Jones; B R Blazar Journal: Transplantation Date: 2001-10-27 Impact factor: 4.939
Authors: J A Belperio; M P Keane; M D Burdick; J P Lynch; Y Y Xue; A Berlin; D J Ross; S L Kunkel; I F Charo; R M Strieter Journal: J Clin Invest Date: 2001-08 Impact factor: 14.808
Authors: John A Belperio; Michael P Keane; Marie D Burdick; Joseph P Lynch; Ying Ying Xue; Kewang Li; David J Ross; Robert M Strieter Journal: J Immunol Date: 2002-07-15 Impact factor: 5.422
Authors: Yunge Zhao; Damien J LaPar; John Steidle; Abbas Emaminia; Irving L Kron; Gorav Ailawadi; Joel Linden; Christine L Lau Journal: J Heart Lung Transplant Date: 2010-12 Impact factor: 10.247
Authors: Mathangi Srinivasan; Ryan Flynn; Andrew Price; Ann Ranger; Jeffrey L Browning; Patricia A Taylor; Jerome Ritz; Joseph H Antin; William J Murphy; Leo Luznik; Mark J Shlomchik; Angela Panoskaltsis-Mortari; Bruce R Blazar Journal: Blood Date: 2011-11-09 Impact factor: 22.113
Authors: Marc O Johnson; Melissa M Wolf; Matthew Z Madden; Gabriela Andrejeva; Ayaka Sugiura; Diana C Contreras; Damian Maseda; Maria V Liberti; Katelyn Paz; Rigel J Kishton; Matthew E Johnson; Aguirre A de Cubas; Pingsheng Wu; Gongbo Li; Yongliang Zhang; Dawn C Newcomb; Andrew D Wells; Nicholas P Restifo; W Kimryn Rathmell; Jason W Locasale; Marco L Davila; Bruce R Blazar; Jeffrey C Rathmell Journal: Cell Date: 2018-11-01 Impact factor: 41.582
Authors: Kylie A Alexander; Ryan Flynn; Katie E Lineburg; Rachel D Kuns; Bianca E Teal; Stuart D Olver; Mary Lor; Neil C Raffelt; Motoko Koyama; Lucie Leveque; Laetitia Le Texier; Michelle Melino; Kate A Markey; Antiopi Varelias; Christian Engwerda; Jonathan S Serody; Baptiste Janela; Florent Ginhoux; Andrew D Clouston; Bruce R Blazar; Geoffrey R Hill; Kelli P A MacDonald Journal: J Clin Invest Date: 2014-08-26 Impact factor: 14.808
Authors: Edouard Forcade; Katelyn Paz; Ryan Flynn; Brad Griesenauer; Tohti Amet; Wei Li; Liangyi Liu; Giorgos Bakoyannis; Di Jiang; Hong Wei Chu; Mercedes Lobera; Jianfei Yang; David S Wilkes; Jing Du; Kate Gartlan; Geoffrey R Hill; Kelli Pa MacDonald; Eduardo L Espada; Patrick Blanco; Jonathan S Serody; John Koreth; Corey S Cutler; Joseph H Antin; Robert J Soiffer; Jerome Ritz; Sophie Paczesny; Bruce R Blazar Journal: JCI Insight Date: 2017-06-15
Authors: Angela Panoskaltsis-Mortari; Matthias Griese; David K Madtes; John A Belperio; Imad Y Haddad; Rodney J Folz; Kenneth R Cooke Journal: Am J Respir Crit Care Med Date: 2011-05-01 Impact factor: 21.405
Authors: Katelyn Paz; Ryan Flynn; Jing Du; Stacey Tannheimer; Amy J Johnson; Shuai Dong; Anne-Katrien Stark; Klaus Okkenhaug; Angela Panoskaltsis-Mortari; Peter T Sage; Arlene H Sharpe; Leo Luznik; Jerome Ritz; Robert J Soiffer; Corey S Cutler; John Koreth; Joseph H Antin; David B Miklos; Kelli P MacDonald; Geoffrey R Hill; Ivan Maillard; Jonathan S Serody; William J Murphy; David H Munn; Colby Feser; Michael Zaiken; Bart Vanhaesebroeck; Laurence A Turka; John C Byrd; Bruce R Blazar Journal: Am J Transplant Date: 2019-03-19 Impact factor: 8.086